L. Wongsrisang

Immunogenicity of heterologous prime/booster-inactivated and adenoviral-vectored COVID-19 vaccine: real-world data

S. Akksilp, Y. Poovorawan, Somchai Thanasitthichai, 2021 .

Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults

Y. Poovorawan, N. Wanlapakorn, R. Yorsaeng, 2021, Vaccine.

Immune response elicited from heterologous SARS-CoV-2 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria)

Y. Poovorawan, S. Vongpunsawad, R. Yorsaeng, 2021, medRxiv.

COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron

Y. Poovorawan, J. Puenpa, T. Duangchinda, 2022, medRxiv.

Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data

Y. Poovorawan, N. Wanlapakorn, R. Yorsaeng, 2022, Vaccine.

Prevalence of antibodies against seasonal influenza A and B viruses among older adults in rural Thailand: A cross-sectional study

Y. Poovorawan, Sumeth Korkong, N. Wanlapakorn, 2021, PloS one.